Fig. 2

CLDN7 promoter DNA methylation is associated with low CLDN7 expression in ccRCC patients. (A) The heatmap between CLDN7 14 methylation region and CLDN7 mRNA expression in TCGA ccRCC dataset (n = 480). The analysis was performed using UCSC Xena. (B) The negative correlation between CLDN7 methylation status and CLDN7 mRNA (a) and protein expression (b) in Kidney Renal Clear Cell Carcinoma (TCGA, Provisional, n = 538) dataset, using cBioPortal. (C) Eight significant DNA hyper-methylated promoter regions (cg00072720, cg11941546, cg14034852, cg05490983, cg15298719, cg03186999, cg11408784 and cg12805420) of CLDN7 in ccRCC tissues compared with normal kidney tissues. The fold change (T/N) more than 1.30 were marked red. (D) Eight DNA hyper-methylated promoter regions (cg00072720, cg11941546, cg14034852, cg05490983, cg15298719, cg03186999, cg11408784 and cg12805420) of CLDN7, were negatively correlated with CLDN7 mRNA expression. The correlation coefficients lower than − 0.3 were marked red. T refers to Tumor tissue of ccRCC, N refers to Normal kidney tissue. *p < 0.05, **p < 0.01